Alex Toohie | Meet the Speakers: Med-Tech Expo 2026

Key Takeaways

• FDA and EU MDR miss mandatory radio‑equipment approvals for many devices
• Wireless medical products often unintentionally fall under radio‑equipment regulations
• Early compliance planning cuts testing time and market‑entry costs
• Element’s framework streamlines approval pathways for connected health devices
• Med‑Tech Expo session offers actionable steps for regulatory efficiency

Pulse Analysis

Regulatory compliance in medical technology has traditionally centered on clinical safety, but a growing subset of devices now incorporates wireless communication, pulling them into the realm of radio‑equipment legislation. In the United States, the FCC’s Part 15 rules and, in the European Union, the Radio Equipment Directive impose testing, labeling, and certification requirements that sit outside the FDA’s 510(k) or the EU’s MDR processes. Companies that fail to recognize this overlap risk costly redesigns, delayed market entry, and potential enforcement actions.

Element Materials Technology has built a specialized advisory model to bridge this gap. By mapping device functionality against radio‑equipment criteria early in the development cycle, the firm helps manufacturers determine whether a product triggers FCC or EU radio approvals. Their approach combines electromagnetic compatibility (EMC) testing, pre‑compliance simulations, and a streamlined documentation package that aligns with both clinical and radio standards. This dual‑track strategy not only trims the overall testing timeline but also reduces the need for redundant lab work, delivering measurable cost savings for startups and established OEMs alike.

The upcoming Med‑Tech Expo session, titled “Beyond the FDA/MDR: The Hidden Radio,” promises concrete tactics for integrating radio‑equipment compliance into product roadmaps. Attendees will learn how to conduct a quick classification check, prioritize low‑risk pathways, and leverage Element’s template‑driven processes to accelerate approvals. For med‑tech innovators, mastering this niche yet critical regulatory layer can be the difference between a timely launch and a market‑entry setback, positioning firms to capitalize on the rapid growth of connected health solutions.